8 participants
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-09-01
- Start Date:
- 2019-11-15
- Completion:
- 2029-02-28
Conditions
- BCR-JAK2 Fusion Protein Expression
- Blasts 20 Percent or Less of Peripheral Blood White Cells
- Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
- Blasts More Than 5 Percent of Peripheral Blood White Cells
- Blasts Under 20 Percent of Bone Marrow Nucleated Cells
- Chronic Eosinophilic Leukemia, Not Otherwise Specified
- Eosinophilia
- Hepatomegaly
- Hypereosinophilic Syndrome
- JAK2 Gene Mutation
- Splenomegaly
- TEL-JAK2 Fusion Protein Expression
Interventions
- DRUG
No Results Yet